SPY343.67+0.29 0.08%
DIA282.71-0.24 -0.08%
IXIC11,557.23+40.74 0.35%

Cerus Corporation Announces Five-Year FDA Contract For Development Of Next Generation Pathogen Reduction Technology To Treat Whole Blood; Contract Value Totals $11.1M

Cerus Corporation (NASDAQ:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathogen reduction (PR)

· 10/13/2020 08:41

Cerus Corporation (NASDAQ:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathogen reduction (PR) treatment of whole blood to reduce the risk of transfusion-transmitted infections. The contract value totals $11.1 million. This research is consistent with the FDA's strategy for developing proactive, foundational interventions to ensure blood safety and availability1.